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6/j.bThis retrospective report compared the results of a reduced-intensity conditioning (RIC) regimen including fludar-
abine (Flu), and very low-dose oral busulfan (BU) (4 mg/kg total dose) in combination with antithymocyte globulin
(ATG) (Flu/ATG/BU) to the classical Flu and low-dose total body irradiation (TBI) (2 Gy) regimen (Flu/TBI) in pa-
tients with lymphoid malignancies.With a median follow-up of 42months, the cumulative incidence of transplant-
related mortality (TRM) was 22% in the Flu/ATG/BU group versus 41% in the Flu/TBI group (P5 .09). Grade 3-4
acute graft-versus-host disease (aGVHD) and extensive chronicGVHD (cGVHD) incidents were 15% versus 44%
(P5 .006), and 12% versus 58% (P5 .0003), in the Flu/ATG/BU group versus the Flu/TBI group, respectively. The
Kaplan-Meier estimate of overall survival (OS) at 2 years was comparable between both groups (71%; 95% confi-
dence interval [CI] 58%-86%, in the Flu/ATG/BUgroupvs 60%; 95%CI 44%-83%, in the Flu/TBI group, P5.20). The
estimate of progression-free survival (PFS) was 63% (95%CI 50%-80%) in the Flu/ATG/BU group versus 52% (95%
CI, 36%-76%) in the Flu/TBI group (P5.18), suggesting that reduced-intensity conditioning (RIC) basedon Flu, very
low-dose BU, and ATG has the potential to induce long-term remissions in patients with lymphoid malignancies.
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bmt.2011.04.010life-threatening malignancies [1]. However, because
of the high incidence of transplant-related mortality
(TRM), this procedure is limited to younger patients
in good medical condition [2]. Reduced-intensity con-
ditioning (RIC) regimens are used with the aim to de-
crease TRM in elderly patients, in heavily pretreated
patients or in patients with medical comorbidities pre-
cluding the use of standard myeloablative preparative
regimens [3,4]. The use of RIC regimens aims to take
advantage of the graft-versus-malignancy effect medi-
ated by the immunocompetent cells of the donor [5].
However, onemust acknowledge that hematologicma-
lignancies encompass a group of chemosensitive dis-
eases, raising concerns that significant reduction of
the intensity of thepreparative regimenmayhave aneg-
ative impact on long-term malignancy control [6-8].
Investigators are currently faced with a dilemma on
how to optimize the potential role of RIC allo-SCT,
while minimizing myeloablation-related toxicity and
maximizing allogeneic immunotherapy. Currently,
several groups have shown that administration of alky-
lating agents (eg, busulfan [BU] or melphalan) and
Biol Blood Marrow Transplant 17:1698-1720, 2011 1699Low-Dose Busulfan-Based RIChighly immunosuppressive drugs, including fludara-
bine (Flu) and/or antithymocyte globulin (ATG), or
low-dose total body irradiation (TBI) can result in du-
rable donor cell engraftment [9]. However, the poten-
tial advantage of 1 RIC protocol over another is not yet
established.This report compared the results of anRIC
regimen including Flu and very low-dose BU (4 mg/kg
total dose) in combination with ATG to the classical
Flu and low-dose TBI (2 Gy) RIC regimen [10] in pa-
tients with lymphoid malignancies.PATIENTS AND METHODS
This retrospective single-center study included 68
patients diagnosed with lymphoid malignancies who
underwent allo-SCT at the University Hospital of
Nantes (CHU de Nantes, France) between January
2003 and May 2009. For the purpose of this analysis,
all patients who received conditioning regimen with
Flu and low-dose TBI (2 Gy) or Flu combined with
very low-dose BU and ATG were included. The pri-
mary endpoint of the study was overall survival (OS).
In our transplant program, eligibility criteria for RIC
allo-SCT included (1) patient age .50 years, (2)
heavily pretreated patients who received auto-SCT
or with more than 2 lines of chemotherapy before
allo-SCT, and (3) patients with poor performance sta-
tus because of significant medical comorbidities as de-
scribed by Sorror et al. [2]. Written informed consent
was obtained from each patient and donor. The study
was approved by the local institutional review board.
All allogeneic grafts were obtained from HLA-A,
HLA-B, HLA-C, HLA-DR, and HLA-DQ-matched
donors. A single HLA mismatch of 10 (at HLA-Cw)
was allowed at the allele level. HLA-DP typing was
not routinely performed at time of this analysis. All
donor–recipient pairs were typed at the allelic level.
They were first typed at the 2-digit level for HLA
class I (HLA-A, HLA-B, and HLA-Cw) and class II
(HLA-DRB1 and HLA-DQB1) using published HLA
class I polymerase chain reaction sequence-specific
oligonucleotide (PCR-SSO) and/or PCR-sequence-
specific primers (PCR-SSP) typing protocols. For
unrelated donors, HLA-A, HLA-B, HLA-Cw,
HLA-DRB1,HLA-B3,HLA-B4, andHLA-B5 subtyp-
ing was performed using different PCR-SSP kits. HLA
typing was performed according to the current use of
the European Federation for Immunogenetics (EFI)
Histocompatibility Laboratory standards.
In this series, a first cohort of 41 consecutive pa-
tients received the very low-dose BU RIC regimen
(Flu/ATG/Bu), consisting of Flu 30 mg/m2/day intra-
venous (i.v.) for 4 consecutive days (2 patients received
a modified schedule for Flu at 25 mg/m2/day i.v. for 5
consecutive days); ATG (Thymoglobuline; Genzyme,
Lyon, France) for a total dose of 5 mg/kg administeredover 2 days (ATG dosage was increased to 12.5 mg/kg
total dose in 2 patients because of a higher risk of
graft-versus-host disease [GVHD], according to the at-
tending physician); and very low-dose oral BU 4 mg/kg
total dose (1 mg/kg every 6 h for 1 day).
A second cohort of 27 consecutive patients re-
ceived the Flu/TBI regimen consisting of Flu 30 mg/
m2/day for 3 consecutive days and low-dose TBI
(2 Gy). In the Flu/TBI cohort, rituximab was added
as part of the conditioning regimen in 10 patients
with chronic lymphocytic leukemia (CLL) at a total
dose of 1375mg/m2. Rituximab was administered on
day 213 (375 mg/m2) and on days 26, 11, and 18
(1000 mg/m2) [11]. Of note, patient allocation to
each conditioning category was mainly dependent on
the time period.
Patients’ characteristics for the entire study popu-
lation and for each conditioning group are detailed in
Table 1. All patients received the preparative regimen
as inpatients in private rooms, and remained hospital-
ized until hematopoietic and clinical recovery. Thirty-
nine donors (57%) wereHLA-identical sibling donors,
26 (38%) were HLA-matched unrelated donors
(MUD), and 3 (4%) were related or unrelated donors
with 1 locus mismatch (1 related and 2 unrelated).
The stem cell source was bone marrow (BM) in 5 cases
(7%) and granulocyte-colony stimulating factor
(G-CSF)-mobilized peripheral blood stem cells
(PBSCs) in the remaining 63 cases (93%). In this se-
ries, the median age was 53 (range: 15-66) years. Thir-
teen patients (32%) were treated for an indolent
lymphoma in the Flu/ATG/BU group versus 12 pa-
tients (44%) in the Flu/TBI group. Fifteen patients
were treated for an aggressive lymphoma (36%) in
the Flu/ATG/BU group versus 5 patients (18%) in
the Flu/TBI group. Two patients had a mantle cell
lymphoma in the Flu/ATG/BU group versus 3 pa-
tients in the Flu/TBI group. Eleven patients (27%)
had Hodgkin’s Disease (HD) in the Flu/ATG/BU
group, and 7 (26%) in the Flu/TBI group.
Supportive care and antimicrobial prophylaxis
were reported previously [12]. For GVHD prophy-
laxis, patients in the Flu/ATG/BU cohort used to re-
ceive either cyclosporine A (CsA) alone in the case of
a matched sibling donor, or CsA and mycophenolate
mofetil (MMF) in the case of a MUD [13] (Table 1).
In the Flu/TBI cohort, GVHD prophylaxis consisted
of CsA and MMF [10]. In both cohorts, CsA was ad-
ministered at a dose of 3 mg/kg/day by continuous in-
travenous infusion starting from day 23 or 22, and
changed to twice daily oral dosing as soon as tolerated
[14]. MMF was given at a fixed oral dose of 2 g/day.
No treatment adjustment was performed for MMF.
MMF was tapered over 4 weeks starting from day
160 and CsA from day 190 if no GVHD appeared.
Of note, during the entire study period, supportive
care was the same. Cytomegalovirus (CMV) infection
Table 1. Study Population Characteristics
Characteristic (%)
Study Population
(N 5 68)
Flu/ATG/BU
(N 5 41)
Flu/TBI
(N 5 27) P
Patient age, median (range) 53 (15-66) 49 (15-63) 54 (27-66) .04
Patient gender
Male 44 (65) 24 (59) 20 (74) .29
Female 24 (35) 17 (41) 7 (26)
Donor gender
Female donor 33 (48) 22 (54) 11 (41) .43
CMV serologic status
Seronegative donor–recipient pair 23 (34) 16 (39) 7 (26) .39
Diagnosis and disease status .34
Indolent NHL* 25 (37) 13 (32) 12 (44) (for comparison of diagnoses)
CR 7 (10) 4 (10) 3 (11)
PR 11 (16) 5 (12) 6 (22)
Relapse/PD 7 (10) 4 (10) 3 (11)
Aggressive NHL† 20 (29) 15 (36) 5 (18)
CR 11 (16) 9 (22) 2 (7)
PR 7 (10) 5 (12) 2 (7) .30
Relapse/PD 2 (3) 1 (2) 1 (4) (for comparison of disease status)
Mantle cell lymphoma 5 (7) 2 (5) 3 (11)
CR 2 (3) 1 (2) 1 (4)
PR 3 (4) 1 (2) 2 (7)
Relapse/PD 0 0 0
Hodgkin’s disease 18 (26) 11 (27) 7 (26)
CR 5 (7) 4 (10) 1 (4)
PR 10 (15) 5 (12) 5 (18)
Relapse/PD 3 (4) 2 (5) 1 (4)
Stem cell source
Bone marrow 5 (7) 3 (7) 2 (7) 1.00
PBSC 63 (93) 38 (93) 25 (93)
Donor type
Matched related donor (MRD) 39 (57) 26 (63) 13 (48)
Matched unrelated donor (MUD) 26 (38) 14 (34) 12 (44)
Mismatch related or unrelated donor (MIS) 3 (4) 1 (2) 2 (7) .30
GVHD prophylaxis
CsA alone 31 (45) 30 (73) 1 (4) <.0001
CsA + MMF 36 (53) 10 (24) 26 (96)
CsA + MTX 1 (1) 1 (2)‡ 0 (0)
NHL indicates non-Hodgkin lymphoma; CR, complete remission; PR, partial remission; PD, progressive disease; PBSC, peripheral blood stem cell; CsA,
Ciclosporine A; MMF, mycophenolate mofetil; MTX, methotrexate; GVHD, graft-versus-host disease; MRD, matched related donor; MUD, matched
unrelated donor; TBI, total body irradiation; DLBCL, diffuse large B-cell lymphoma.
*Indolent NHL: 14 chronic lymphocytic leukemia, 3 Waldenstrom Macroglubulinemia, and 8 follicular lymphoma.
†Aggressive NHL: 7 DLBCL, 9 transformed lymphoma, 3 angio-immunoblastic T cell lymphoma, and 1 histiocytic lymphoma.
‡One patient from this cohort did not wish to take oral MMF and thus received CsA and short-course methotrexate (15 mg/m2 at day +1, 10 mg/m2 at
days +3 and +6).
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ucts were filtered, irradiated, and CMV screened. In
the first 100 days post-allo-SCT, patients were as-
sessed at least once per week for CMV reactivation
by PCR assay in order to initiate preemptive ganciclo-
vir therapy. Acute GVHD (aGVHD)was evaluated ac-
cording to the Seattle standard criteria.
OS and progression-free survival (PFS) were cal-
culated by the Kaplan-Meier method and subgroups
were compared using the log-rank test. For categoric
variables, comparison of the Flu/TBI group and the
Flu/ATG/BU group was performed using the chi-
square test for patient and donor gender, CMV sero-
logic status, and the Fisher exact test for diagnosis,
disease status at transplantation, stem cell source,
donor type, GVHD prophylaxis, cause of death, and
disease status at last follow-up. For continuous data,comparison between regimens was performed using
the Mann-Whitney test for patient age, median
follow-up, and median time to neutrophils .0.5 G/L.
Probabilities of relapse, TRM, and GVHD were cal-
culated using the cumulative incidence procedure,
and comparisons were performed using the Gray
test. All data were computed using the R package
(R Development Core Team, 2006. R: A language
and environment for statistical computing. R Founda-
tion for Statistical Computing, Vienna, Austria. ISBN
3-900051-07-0, http://www.R-project.org).RESULTS
The overall median follow-up was 42 (range: 4-85)
months among surviving patients. Because of the study
design, themedian follow-up in the Flu/TBI groupwas
Table 2. Transplantation-Related Events
Characteristic (%) Study Population (N 5 68) Flu/ATG/BU (N 5 41) Flu/TBI (N 5 27) P
Median follow-up, months (range) 42 (4-85) 49 (15-85) 33 (4-51) .002
OS at 2 years (95%CI) 66 (56-79) 71 (58-86) 60 (44-83) .20
PFS at 2 years (95%CI) 59 (48-72) 63 (50-80) 52 (36-76) .18
TRM (cumulative incidence) 29% 22% 41% .09
Cause of death
GVHD 9 (13) 3 (7) 6 (22)
Infections 10 (15) 6 (15) 4 (15) .18
Relapse/progression 5 (7) 4 (10) 1 (4)
Acute GVHD indicates acute graft-versus-host disease; CI, confidence interval; TBI, total body irradiation; OS, overall survival; Flu, fludarabine; ATG,
antithymocyte globulin; BU, busulfan.
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Transplant-related events are summarized in Table 2.
Patients from the Flu/ATG/BU group engrafted at
a median of 17 (range: 0-30) days after allo-SCT,
whereas patients treated with Flu/TBI engrafted at
amedian of 15 (range: 0-25) days (P5 .02). One patient
conditioned with Flu/TBI had a spontaneous autolo-
gous reconstitution subsequent to primary graft failure.
Of the 68 patients included in this study, 24 died during
the follow-up period, and 44 are still alive at last follow-
up (2-year OS of 66%; 95% confidence interval [CI],
56%-79%). The 2-year OS was comparable betweenFigure 1. Outcome after allo-HSCT between the Flu/ATG/BU group (dashed
incidence of TRM; (C) cumulative incidence of grade 3-4 aGVHD; (D) cumulatboth groups (71%; 95% CI, 58%-86%) in the Flu/
ATG/BU group versus 60% (95% CI, 44%-83%) in
the Flu/TBI group (P 5 .20) (Figure 1A). Five deaths
were directly attributed to disease progression or re-
lapse, whereas death was related to allo-SCT in 19
cases, of which 9 deaths were attributed to aGVHD
or chronic GVHD (cGVHD) and 10 patients to infec-
tions. At 2 years, the overall cumulative incidence of
TRMwas 29%. In the Flu/ATG/BUgroup, the cumu-
lative incidence of TRM was 22%, whereas TRM was
41% in the Flu/TBI group (P 5 .09) (Figure 1B).
The cumulative incidence of severe grade 3-4 aGVHDline) and the Flu/TBI group (solid line). (A) Two-year OS; (B) cumulative
ive incidence of extensive chronic GVHD. x-axis: months post-allo-SCT.
1702 Biol Blood Marrow Transplant 17:1698-1720, 2011F. Malard et al.was 15% (n56) in theFlu/ATG/BUgroup and44% (n
5 12) in the Flu/TBI group (P 5 .006) (Figure 1C).
The cumulative incidence of extensive cGVHD was
12% (n 5 5) in the Flu/ATG/BU group versus 58%
(n 5 12) in the Flu/TBI group (P 5 .0003)
(Figure 1D). Relapse or progression occurred in 14 pa-
tients at a median time of 169 (range: 8-352) days after
RIC allo-SCT. The cumulative incidence of relapse or
progression from allo-SCT was 20% and 22% in the
Flu/TBI and the Flu/ATG/BU regimen, respectively
(P5 .89). TheKaplan-Meier estimate of PFS at 2 years
was 63% (95%CI, 50%-80%) in patients receiving the
Flu/ATG/BU regimen versus 52% (95% CI, 36%-
76%) in patients receiving the Flu/TBI regimen (P 5
.18).DISCUSSION
In this study, we compared retrospectively the
outcomes following the commonly used Flu/TBI RIC
regimen versus a very low-dose BU regimen in patients
with lymphoidmalignancies. It is likely that these 2 reg-
imens are of equivalent myelosuppressive intensity in
the spectrum of RIC regimens according to the work-
ing definitions published recently by Bacigalupo et al.
[15]. Indeed, although statistically different, the delays
for achieving an absolute neutrophil count (ANC).0.5
G/L is medically comparable and further supports this
similarity. However, despite these similarities in terms
of ‘‘intensity,’’ our data are suggestive of some differ-
ences between these 2 approaches, especially in terms
of GVHD severity. Indeed, we found a higher overall
incidence of severe aGVHD after Flu/TBI [16]. The
difference in terms of severe aGVHD and cGVHD
translated into a trend of higher TRM in the Flu/TBI
regimen. Also, the lower rates of GVHD in the Flu/
ATG/BU were not apparently associated with an in-
creased risk of relapse, further supporting the beneficial
role of this category of conditioning regimens.
Our data are comparable to those previously pub-
lished by Armand et al. [17], who analyzed the out-
come of 87 patients with advanced lymphoma who
underwent allo-SCT after a similar RIC regimen con-
sisting of fludarabine and very low-dose i.v. BU. In the
latter study, the 1-year cumulative incidence of TRM
was 13%, the incidence of grade 3-4 aGVHD was
11%, and the 2-year cumulative incidence of cGVHD
was 68%. The higher incidence of cGVHD in the Flu/
TBI group, and in the study by Armand et al. [17] com-
pared to our study, is likely related to the absence of
use of ATG, which has been increasingly proven to ex-
ert a protective effect against severe cGVHD [18-20].
However, one should bear in mind that our re-
sults looking at the Flu/ATG/BU and Flu/TBI regi-
mens are based on a retrospective comparison of
a limited sample of patients. Moreover, these cohortsexhibit various types of lymphoma, making the com-
parison between relapse/progression rates and PFS
uneasy. Indeed, the Seattle group has pioneered the
low-dose TBI-based conditioning regimen based on
studies in a canine transplantation model [21]. The
regimen consists of 2-Gy TBI with or without Flu
and postgrafting immunosuppression with a calci-
neurin inhibitor and MMF. The regimen has relied
almost entirely on the graft-versus-tumor (GVT) ef-
fects for treating malignancies. This type of regimen
is usually well tolerated in older and/or medically in-
firm patients. On the other hand, the Flu/TBI plat-
form is associated with relatively high relapse rates,
especially in patients with advanced disease [22]. On
the other hand, the relapse rate was not increased
in the current group of patients who received the
Flu/ATG/BU regimen despite a lower incidence of
GVHD. Interestingly, in an effort to reconcile the
potential advantages of the Flu/TBI and Flu/ATG/
BU approaches, Russel et al. [23] could show that
the combination of i.v. BU, Flu, ATG, and TBI 4
Gy provides a well-tolerated regimen with antileuke-
mic activity comparable to that of other conventional
myeloablative conditioning regimens [23]. Similarly,
a series of 65 patients reported by Grosskreutz
et al. [24] suggested that the addition of ATG to
TBI 2 Gy and Flu resulted in an improved transplan-
tation outcome in patients with lymphoid malignan-
cies.
In conclusion, our results suggest that RIC allo-
SCT based on Flu, very low-dose BU, and ATG has
the potential to induce long-term remissions in pa-
tients with lymphoid malignancies. Such a regimen
compares favorably to the widely used Flu/TBI regi-
men, warranting prospective comparative studies.ACKNOWLEDGMENTS
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